16 September 2021 - final results
The AIM-listed pharmaceutical and services group has announced its results for the year to 30 June with adjusted revenues rising by 7% to £458.6m although adjusted pre-tax profits fell by 15% to £92.3m. Earnings per share on the same basis were 14% lower at 55.9p and the dividend was maintained at 7.61p per share. Although the results were broadly in line with expectations, a cautionary note on prospects for the current financial year has resulted in a sharp fall in the share price. Lower sales than expected of Erwinase . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
